• Photothermal-CD47 Blockade Synergy Reshapes OSCC Immunity

  2026-06-23

  This study demonstrates that photothermal therapy (PTT) combined with CD47 blockade significantly enhances macrophage-mediated anti-tumor activity in oral squamous cell carcinoma (OSCC). Key mechanistic findings reveal that PTT triggers immunogenic cell death and extracellular matrix remodeling, overcoming barriers to effective immunotherapy in solid tumors.

• Copper-Coordinated Nanoplatforms for Multimodal Cancer Thera

  2026-06-23

  This study introduces a baicalein-copper nanoassembly capable of bone-penetrating, tumor-targeted delivery, enabling synergistic chemodynamic and photodynamic therapy with the induction of cuproptosis. The platform's TME-responsive copper release, ROS generation, and selective tumor accumulation offer a promising strategy for overcoming limitations of current cancer therapies.

• Microglial BDNF Drives Arketamine’s Antidepressant Effects v

  2026-06-22

  He et al. reveal that microglia-derived BDNF is essential for arketamine’s rapid and sustained antidepressant-like effects in mice, acting through cortico-accumbal neural circuits. Their work clarifies how arketamine modulates neuronal activity and synaptic transmission, suggesting new mechanistic targets for depression therapeutics.

• Polymeric Nanozymes Target Intramacrophage Bacteria in CRC I

  2026-06-22

  This study introduces self-activatable polymeric nanozymes engineered to selectively eradicate Fusobacterium nucleatum within tumor-associated macrophages in colorectal cancer. By remodeling the immunosuppressive microenvironment, the approach markedly enhances the efficacy of CD47 blockade immunotherapy and offers a paradigm for targeting microbial-driven resistance in solid tumors.

• XAV-939: Precision Modulation of Wnt/β-Catenin in Disease Mo

  2026-06-21

  XAV-939 (NVP-XAV939) offers highly selective tankyrase inhibition, enabling reproducible dissection of Wnt/β-catenin signaling in oncology, fibrosis, and stem cell differentiation studies. This guide details evidence-backed workflows, troubleshooting strategies, and translational insights from neuroinflammation research—empowering you to maximize the impact of XAV-939 from APExBIO in advanced experimental designs.

• ARL4C Drives RA Progression via FLS Proliferation and Macrop

  2026-06-20

  This study reveals that ARL4C is a key molecular driver in rheumatoid arthritis (RA), facilitating fibroblast-like synoviocyte (FLS) proliferation and influencing macrophage polarization. Integrated single-cell and bulk RNA sequencing, along with functional assays, identify ARL4C as a promising therapeutic target for halting RA progression and joint damage.

• GMDS Drives Fucosylation and Tumorigenesis in MYCN-Amplified

  2026-06-19

  This study identifies GDP-mannose 4,6-dehydratase (GMDS) as a critical regulator of core fucosylation and tumor progression in MYCN-amplified neuroblastoma. By linking GMDS-driven de novo GDP-fucose synthesis to tumor aggressiveness and poor prognosis, the research highlights a metabolic vulnerability that could inform future therapeutic strategies.

• Dual SMAD and Wnt Inhibition Enables High-Purity iPSC-RGC Di

  2026-06-19

  This study establishes a robust, chemically defined protocol for differentiating human induced pluripotent stem cells into retinal ganglion cells by dual inhibition of SMAD and Wnt pathways. Achieving over 80% RGC purity without genetic modification, the method reduces variability and offers a reliable platform for glaucoma and neurodegenerative disease modeling.

• Angiotensin 1/2 (1-6): Mechanistic Leverage for Translationa

  2026-06-18

  Explore how the Asp-Arg-Val-Tyr-Ile-His hexapeptide Angiotensin 1/2 (1-6) offers mechanistic precision and strategic value for researchers in cardiovascular, renal, and viral pathogenesis domains. This article integrates state-of-the-art experimental insight, discusses translational relevance, and provides practical protocol guidance, directly referencing leading literature and APExBIO’s high-purity reagent.

• GPR35-KLF5 Circuitry Orchestrates Epithelial Repair in DSS C

  2026-06-18

  This study uncovers a metabolic gatekeeping mechanism in which GPR35 detects tryptophan metabolite signals to trigger KLF5-mediated repair of intestinal epithelial injury, central to ulcerative colitis pathogenesis. Using a DSS-induced colitis mouse model, the authors delineate the molecular pathway linking damage sensing to epithelial regeneration, providing actionable insight for translational IBD research.

• Novobiocin Workflows: Antiparasitic and Antiviral Applicatio

  2026-06-17

  Novobiocin's dual role as an aminocoumarin antibiotic and Hsp90 inhibitor enables advanced antibacterial, antiparasitic, and antiviral workflows. This guide details experimental protocols, troubleshooting insights, and cross-domain strategies for maximizing research outcomes with this versatile compound.

• Go 6983: Advancing PKC Pathway Research from Mechanism to Tr

  2026-06-17

  This article provides a mechanistic and strategic roadmap for translational researchers leveraging Go 6983 (pan-PKC inhibitor) to dissect and manipulate PKC-dependent signaling in cancer, EMT, and metabolic control of cell fate. Integrating insights from recent studies—including the WDR36-glycolysis axis in embryonic development—this piece offers actionable protocol guidance, positions Go 6983 within the competitive landscape, and articulates future translational opportunities, with a focus on credible, evidence-linked recommendations.

• Moxifloxacin in Advanced Toxicity & Metabolic Pathway Resear

  2026-06-16

  Explore Moxifloxacin’s role as a fluoroquinolone antibiotic in probing antibiotic toxicity and metabolic responses. This article offers a deep, mechanistic analysis for researchers seeking to advance the frontiers of cellular and metabolic pathway studies.

• Polyethylenimine Linear (PEI) MW 40,000: Enabling Next-Gen G

  2026-06-16

  This article provides a mechanistic and strategic analysis of Polyethylenimine Linear (PEI), MW 40,000, emphasizing its critical role in translational research. It bridges foundational insights with new oncology findings, focusing on lncRNA-driven cuproptosis in breast cancer and the practicalities of high-efficiency DNA transfection. Strategic guidance is provided for researchers seeking scalable, reproducible solutions for transient gene expression and recombinant protein production, with a focus on clinical impact and competitive positioning.

• Filipin III: Accelerating Immunometabolic Discovery in Trans

  2026-06-15

  Filipin III, a polyene macrolide antibiotic, has emerged as an indispensable tool for membrane cholesterol visualization and mechanistic dissection of cholesterol-driven immunometabolism. This thought-leadership article integrates recent breakthroughs—including the role of cholesterol metabolites in tumor-associated macrophage reprogramming—with actionable guidance for translational researchers. By bridging biological rationale, validated protocols, and strategic outlook, we reveal how APExBIO’s Filipin III enables high-impact discoveries in the evolving landscape of immunometabolic disease.

736 records 11/50 page Previous Next First page 上5页 1112131415 下5页 Last page